MAGED4 Expression in Glioma and Upregulation in Glioma Cell Lines with 5-Aza-2'-Deoxycytidine Treatment

  • Zhang, Qing-Mei (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Shen, Ning (Department of Oral and Maxillofacial Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region) ;
  • Xie, Sha (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Bi, Shui-Qing (Department of Neurosurgery, First Affiliated Hospital, Guangxi Medical University) ;
  • Luo, Bin (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Lin, Yong-Da (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Fu, Jun (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Zhou, Su-Fang (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Luo, Guo-Rong (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Xie, Xiao-Xun (Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University) ;
  • Xiao, Shao-Wen (Department of Neurosurgery, First Affiliated Hospital, Guangxi Medical University)
  • Published : 2014.04.30


Melanoma-associated antigen (MAGE) family genes have been considered as potentially promising targets for anticancer immunotherapy. MAGED4 was originally identified as a glioma-specific antigen. Current knowledge about MAGED4 expression in glioma is only based on mRNA analysis and MAGED4 protein expression has not been elucidated. In the present study, we investigated this point and found that MAGED4 mRNA and protein were absent or very lowly expressed in various normal tissues and glioma cell line SHG44, but overexpressed in glioma cell lines A172,U251,U87-MG as well as glioma tissues, with significant heterogeneity. Furthermore, MAGED4 protein expression was positively correlated with the glioma type and grade. We also found that the expression of MAGED4 inversely correlated with the overall methylation status of the MAGED4 promoter CpG island. Furthermore, when SHG44 and A172 with higher methylation were treated with the DNA demethylating agent 5-aza-2'-deoxycytidine (5-AZA-CdR) reactivation of MAGED4 mRNA was mediated by significant demethylation in SHG44 instead of A172. However, 5-AZA-CdR treatment had no effect on MAGED4 protein in both SHG44 and A172 cells. In conclusion, MAGED4 is frequently and highly expressed in glioma and is partly regulated by DNA methylation. The results suggest that MAGED4 might be a promising target for glioma immunotherapy combined with 5-AZA-CdR to enhance its expression and eliminate intratumor heterogeneity.


  1. Wischnewski F, Pantel K, Schwarzenbach H (2006). Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res, 4, 339-49.
  2. Sigalotti L, Fratta E, Coral S, et al (2004). Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2’-deoxycytidine. Cancer Res, 64, 9167-71.
  3. Thaker PH, Deavers M, Celestino J, et al (2004). EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res, 10, 5145-50.
  4. Weber J, Salgaller M, Samid D, et al (1994). Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’-deoxycytidine. Cancer Res, 54, 1766-71.
  5. Wu TF, Zhang W, Su ZP, et al (2012). UHRF2 mRNA expression is low in malignant glioma but silencing inhibits the growth of U251 glioma cells in vitro. Asian Pac J Cancer Prev, 13, 5137-42.
  6. Yang L, Ng KY, Lillehei KO (2003). Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control, 10, 138-47.
  7. Zeybek U, Yaylim I, Ozkan NE, et al (2013). Cyclin D1 Gene G870A Variants and Primary Brain Tumors. Asian Pac J Cancer Prev, 14, 4101-6.
  8. Zhang J, Yu J, Gu J, et al (2004). A novel protein-DNA interaction involved with the CpG dinucleotide at -30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene. Cell Res, 14, 283-94.
  9. Zhang SC, Huang P, Zhao YX, et al (2013). Soluble expression of recombinant human Smp30 for detecting serum Smp30 antibody levels in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 14, 2383-6.
  10. Ohgaki H, Kleihues P (2005). Epidemiology and etiology of gliomas. Acta Neuropathol, 109, 93-108.
  11. Luo B, Yun X, Fan R, et al (2013). Cancer testis antigen OYTES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol, 6, 2835-45.
  12. Meek DW, Marcar L (2012). MAGE-A antigens as targets in tumour therapy. Cancer Lett, 324, 126-32.
  13. Morse MA, Garst J, Osada T, et al (2005). A phase I study of dexosome immunotherapy in patients with advanced nonsmall cell lung cancer. J Transl Med, 3, 9.
  14. Prins RM, Odesa SK, Liau LM (2003). Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res, 63, 8487-91.
  15. Rosenberg SA, Yang JC, Restifo NP (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med, 10, 909-15.
  16. Sampson JH, Archer GE, Ashley DM, et al (1996). Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA, 93, 10399-404.
  17. Sasaki M, Nakahira K, Kawano Y, et al (2001). MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res, 61, 4809-14.
  18. Serrano A, Garcia A, Abril E, Garrido F, Ruiz-Cabello F (1996). Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int J Cancer, 68, 464-70.<464::AID-IJC11>3.0.CO;2-5
  19. Sigalotti L, Coral S, Nardi G, et al (2002). Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother, 25, 16-26.
  20. Germano S, Kennedy S, Rani S, et al (2011). MAGED4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer, 130, 1991-2002.
  21. Dhodapkar MV, Osman K, Teruya-Feldstein J, et al (2003). Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun, 3, 9.
  22. Dos Santos NR, Torensma R, De Vries TJ, et al (2000). Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res, 60, 1654-62.
  23. Duffour MT, Chaux P, Lurquin C, et al (1999). A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol, 29, 3329-37.<3329::AID-IMMU3329>3.0.CO;2-7
  24. Inoue H, Mori M, Honda M, et al (1995). The expression of tumor-rejection antigen “MAGE” genes in human gastric carcinoma. Gastroenterology, 109, 1522-5.
  25. Ito S, Kawano Y, Katakura H, et al (2006). Expression of MAGED4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer. Lung Cancer, 51, 79-88.
  26. Kawano Y, Sasaki M, Nakahira K, et al (2001). Structural characterization and chromosomal localization of the MAGE-E1 gene. Gene, 277, 129-37.
  27. Kramer BF, Schoor O, Kruger T, et al (2005). MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther, 4, 943-8.
  28. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109.
  29. Chi DD, Merchant RE, Rand R, et al (1997). Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol, 150, 2143-52.
  30. Ahmed Ali HA, Di J, Mei W, et al (2014). Antitumor activity of lentivirus-mediated interleukin-12 gene modified dendritic cells in human lung cancer in vitro. Asian Pac J Cancer Prev, 15, 611-6.
  31. Becher B, Prat A, Antel JP (2000). Brain-immune connection:immuno-regulatory properties of CNS-resident cells. Glia, 29, 293-304.<293::AID-GLIA1>3.0.CO;2-A
  32. Cen YH, Guo WW, Luo B, et al (2012). Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell Biol Int, 36, 917-22.
  33. Chong CE, Lim KP, Gan CP, et al (2012). Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. Cancer Lett, 321, 18-26.
  34. Coral S, Sigalotti L, Altomonte M, et al (2002). 5-aza-2’-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res, 8, 2690-5.

Cited by

  1. Effect of Cisplatin on the Frequency and Immuno-inhibitory Function of Myeloid-derived Suppressor Cells in A375 Melanoma Model vol.16, pp.10, 2015,
  2. Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing vol.11, pp.8, 2016,
  3. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy vol.241, pp.1, 2016,